For almost 30 years, urgent revascularization termed primary percutaneous coronary
intervention has been a cornerstone of modern care for acute myocardial infarction (AMI). It …

Percutaneous ventricular assist devices (pVADs) are increasingly being used because of
improved experience and availability. The Impella (Abiomed), a percutaneous microaxial …

Background: The Impella® percutaneous left ventricular assist device has been available in
Japan since 2017. This is the first large-scale registry study to analyze the efficacy and …

Ventricular assist devices (VADs) offer mechanical support for patients with cardiogenic
shock by unloading the impaired ventricle and increasing cardiac outflow and subsequent …

The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary
mechanical circulatory support in various clinical scenarios has been increasing …

Heart failure (HF) is one of the leading causes of global health impairment. Current drugs
are still limited in their effectiveness in the treatment and reversal of HF: for example, drugs …

Acute kidney injury is one of the most frequent and prognostically relevant complications in
cardiogenic shock. The purpose of this study was to evaluate the potential effect of the …

Ventricular septal defect (VSD) is a rare but severe complication of myocardial infarction
(MI). Temporary mechanical circulatory support (MCS) can be used as a bridge to VSD …

In the last decades, outcomes significantly improved for both heart transplantation and
LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart …

Background: The management of cardiogenic shock (CS) after ACS has evolved over time,
and the development of a multidisciplinary team-based approach has been shown to …